SPDR® S&P Pharmaceuticals ETF

Latest SPDR® S&P Pharmaceuticals ETF News and Updates

  • uploads///Chart
    Company & Industry Overviews

    Merck’s Valuation Cheat Sheet for Fiscal 1Q16

    Merck & Co.’s (MRK) current valuation is neither high nor low. Its valuation multiple has followed the industry’s overall trend over the last five years.

    By Mike Benson
  • uploads///ibrance
    Company & Industry Overviews

    Ibrance Is the Only Registered CDK 4/6 Inhibitor for Breast Cancer

    Since its launch in February 2015, Pfizer’s Ibrance has quickly captured the advanced breast cancer market and has reached more than 40,000 patients.

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    How Analysts Rate Bristol-Myers Squibb in 1Q18

    Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18.

    By Mike Benson
  • uploads///thermometer _
    Earnings Report

    Eli Lilly and Co.’s Strong Q1 Results, Updated 2018 Guidance

    Eli Lilly and Co. reported revenues of ~$5.7 billion for 1Q18 today, reflecting 9% growth from 1Q17.

    By Mike Benson
  • uploads///Acq
    Company & Industry Overviews

    Mylan’s Recent Acquisitions Continue to Strengthen Its Position in International Markets

    Mylan takes an M&A strategy to save time related to compliance activities for obtaining regulatory approvals across various international markets.

    By Seth Richards
  • uploads///pill _
    Healthcare

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

    By Kenneth Smith
  • uploads///aerial view of various medical pills pharmaceutical
    Company & Industry Overviews

    An Easier Way to Understand the Pharma Industry

    In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

    By Sybil Prowse
  • uploads///JNJ
    Healthcare

    JNJ Stock Emerging from a Dark Decade

    In 2019, JNJ stock’s 12% return has lagged the S&P’s 27% return by a wide margin. JNJ has lagged the SPDR S&P Pharmaceuticals ETF (XPH) by 2%.

    By Michael Bracken
  • uploads///BMYcelgene
    Company & Industry Overviews

    What to Expect from BMY’s Celgene Acquisition

    The acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) brings together both the company’s leading franchises.

    By Daniel Collins
  • uploads///Chart
    Healthcare

    A Closer Look at the Allergan–Bonti Deal

    On September 14, Allergan (AGN) announced the acquisition of Bonti Inc., a clinical-stage biotechnology company.

    By Mike Benson
  • uploads///Chart  ETFs
    Healthcare

    How Pharmaceutical ETFs Have Performed in 2018

    The SPDR S&P Pharmaceuticals ETF holds ~5.0% of its total investments in Eli Lilly and Company (LLY).

    By Mike Benson
  • uploads///medic _
    Company & Industry Overviews

    Pfizer Announces Results for JAVELIN Renal 101 Study

    Pfizer (PFE) and Merck announced in a press release today positive top-line results for their JAVELIN Renal 101 study, which evaluated a combination of Bavencio (avelumab) and Inlyta (axitinib).

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    Pfizer’s EC Approval of Xeljanz for Active Psoriatic Arthritis

    Pfizer (PFE) announced in a press release yesterday that the European Commission has approved its marketing authorization application for Xeljanz in combination with methotrexate for active psoriatic arthritis.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Eli Lilly’s Endocrine Products Performed in 4Q17

    Eli Lilly and Company’s (LLY) Human Pharmaceuticals segment includes the endocrine products Humalog, Humulin, and Forteo.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Merck’s Business Segments Performed

    Merck reported 3% growth in revenues to ~$10.4 billion during 4Q17 as compared to 4Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    These Pfizer Products Saw Declining Sales in 4Q17

    A few products in Pfizer’s (PFE) portfolio reported declining sales in 4Q17 following their loss of market share to the competition.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Comparing Eli Lilly’s Post-4Q17 Valuation

    Eli Lilly’s valuation In 4Q17, Eli Lilly and Company (LLY) surpassed Wall Street analysts’ EPS (earnings per share) and revenue estimates of $1.07 and ~$5.9 billion, respectively, reporting EPS of $1.14 on revenue of ~$6.2 billion. The above chart shows Eli Lilly’s EPS and revenue since 1Q16. In fiscal 2017, Eli Lilly reported EPS of $4.28 on […]

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What’s Pfizer’s Valuation after 4Q17 Earnings?

    Pfizer (PFE) reported 1% growth in revenues to $13.7 billion during 4Q17 as compared to revenues of $13.6 billion during 4Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Eli Lilly’s 4Q17 Estimates: Elanco

    Elanco is expected to report growth in revenues during 4Q17, following strong sales and a favorable impact of foreign exchange.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Pharmaceuticals Business in 4Q17

    Johnson & Johnson (JNJ) reported ~48.0% of its total revenues from the Pharmaceuticals business during 4Q17, making it the company’s largest revenue contributor.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Pfizer: Revenue Growth Is Expected in 4Q17

    Wall Street analysts expect Pfizer’s (PFE) revenues to increase ~0.7% to $13.72 billion during 4Q17—compared to revenues of $13.63 billion during 4Q16.

    By Mike Benson
  • uploads///Chart  AH
    Company & Industry Overviews

    Merck & Co.’s Animal Health Business in 3Q17

    Merck’s (MRK) Animal Health segment’s total revenues increased ~16% to $1 billion in 3Q17 compared to $865 million in 3Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Revenue Estimates for 4Q17

    Johnson & Johnson’s (JNJ) Pharmaceutical segment contributes more than 45% to total revenues. In 4Q17, it’s expected to report growth in operating revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Recent Developments for Mylan

    Recent developments reported by Mylan (MYL) include commercial developments as well as product developments. Let’s take a closer look.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Johnson & Johnson’s Valuation in December 2017

    On December 27, 2017, Johnson & Johnson (JNJ) was trading at a forward price-to-earnings multiple of ~17.8x compared to the industry average of 15.8x.

    By Mike Benson
  • uploads///NET SALES EPS GROWTH MYL
    Consumer

    Mylan: How Its Performance Contributed to Its Valuation

    In this final series of our three-part series, we’ll be looking at the last seven stocks among the top 18 cheap stocks in the S&P 500 for 2018.

    By Amanda Lawrence
  • uploads///Celebrex
    Company & Industry Overviews

    A Look at How These Pfizer Drugs Have Performed in 2017

    In 3Q17, Pfizer’s (PFE) Celebrex generated revenues of $212 million, a ~9% increase on a year-over-year (or YoY) basis and a 19% increase on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Merck’s 3Q17 Revenues Could Rise

    Analysts expect Merck’s (MRK) revenues for 3Q17 to be around $10,546 million, nearly a 0.1% increase as compared to the revenues of $10,536 million reported for 3Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    These Factors Affected Johnson & Johnson’s Revenues in 2Q17

    Johnson & Johnson (JNJ) reported a 2.9% increase in its revenues at constant exchange rates in 2Q17.

    By Mike Benson
  • uploads///Chart  Keytruda Revenues
    Company & Industry Overviews

    Introducing Merck’s 2Q17 Immuno-Oncology Blockbuster

    For 2Q17, Keytruda reported revenues of $881 million, which represents 183% growth at constant exchange rates.

    By Mike Benson
  • uploads///Chart  Cardio
    Company & Industry Overviews

    Eli Lilly’s Cardiovascular Products in 2Q17

    Eli Lilly and Co.’s (LLY) cardiovascular franchise includes two drugs—Cialis and Effient. These drugs comprise ~15.0% of the company’s total revenues.

    By Mike Benson
  • uploads///Chart  Eliquis
    Company & Industry Overviews

    Performance of Bristol-Myers Squibb’s Eliquis in 2Q17

    Bristol Myers Squibb’s (BMY) cardiovascular portfolio includes the blockbuster drug Eliquis.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Defitelio Continues to Demonstrate Robust Demand Trends in 2017

    Jazz Pharmaceuticals expects Defitelio to report revenues in the range of $130 million to $150 million globally in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Jazz Is Expected to Report a Robust Revenue Growth Rate

    On August 3, JAZZ managed to secure regulatory approval from the FDA for its innovative drug, Vyxeos, as a treatment option for two types of acute myeloid leukemia.

    By Margaret Patrick
  • uploads///National Health Expenditure as of
    Macroeconomic Analysis

    The Hybrid US Healthcare System: An Overview

    The US healthcare system is unique in the developed world as it lacks a uniform system and, according to Emanuel, had been largely inefficient before Obamacare.

    By Mary Sadler
  • uploads///Chart
    Company & Industry Overviews

    Gardasil Driving Merck & Co.’s Vaccines Business in 4Q16

    The total sales for MRK’s Gardasil franchise during 4Q16 totaled $542 million, an increase of ~9% over $497 million for 4Q15.

    By Mike Benson
  • uploads///pfizers patents
    Company & Industry Overviews

    Loss of Patent Protection to Drag Pfizer’s Top Line

    With the loss of patent protection for its flagship drug, Lipitor, Pfizer’s revenue fell to $48.8 billion in 2015, compared to $67 billion in 2010.

    By Jillian Dabney
  • uploads///Opdivo and keytruda
    Company & Industry Overviews

    Keytruda Leads over Opdivo in Head and Neck Cancer Treatment

    CheckMate-141 Bristol-Myers Squibb’s (BMY) CheckMate-141 evaluated Opdivo for the treatment of squamous cell carcinoma of the head and neck. The study was stopped after meeting the primary endpoint in January 2016. The drug is under priority review by the FDA with an action date set for November 11, 2016. With similar approved indications, Opdivo and Merck’s (MRK) […]

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    A Look at Gardasil and Merck & Co.’s Vaccines Business

    Gardasil, a vaccine for the prevention of strains of the human papillomavirus (or HPV) that are sexually transmitted, is Merck & Co.’s leading vaccines franchise.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Akorn in 2016: What Are Its Key Risk Factors?

    In addition to industry-specific risks faced by all generic pharmaceutical players, Akorn (AKRX) faces certain company-specific risks.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    What Are Merck’s Key Diabetes Products?

    Januvia and Janumet are two blockbuster drugs in Merck’s (MRK) diabetes franchise.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Januvia and Janumet: Merck’s Blockbuster Diabetes Drugs

    Januvia and Janumet are Merck & Co.’s (MRK) blockbuster diabetes drugs. They’re are used to lower blood sugar levels in patients with Type 2 diabetes.

    By Mike Benson
  • uploads///acquisitions
    Company & Industry Overviews

    How Horizon Became a Growth Stock

    Over the past 18 months, Horizon Pharma has acquired three orphan drugs. The acquisition of Hyperion Therapeutics in May 2015 gave it Ravicti and Buphenyl.

    By Jillian Dabney
  • uploads///Therapeutic Area
    Company & Industry Overviews

    Mylan Product Portfolio across Key Therapeutic Areas

    Mylan is a leading pharmaceutical company that operates in more than 140 countries and operates across five different therapeutic areas.

    By Seth Richards
  • uploads///Article
    Company & Industry Overviews

    How to arrive at valuations for big pharma

    The PE ratio for global big pharma increased from 14.9x in 2011 to 26x in 2014. This trend is a measure of increasing investor confidence.

    By Mike Benson
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.